JP7602457B2 - ペプチド核酸を基盤としたアジュバント - Google Patents

ペプチド核酸を基盤としたアジュバント Download PDF

Info

Publication number
JP7602457B2
JP7602457B2 JP2021524929A JP2021524929A JP7602457B2 JP 7602457 B2 JP7602457 B2 JP 7602457B2 JP 2021524929 A JP2021524929 A JP 2021524929A JP 2021524929 A JP2021524929 A JP 2021524929A JP 7602457 B2 JP7602457 B2 JP 7602457B2
Authority
JP
Japan
Prior art keywords
peptide
nucleic acid
adjuvant
administration
peptide nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524929A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020246584A1 (https=
Inventor
亮大郎 三股
明日美 神田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Denki Kagaku Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd, Denki Kagaku Kogyo KK filed Critical Denka Co Ltd
Publication of JPWO2020246584A1 publication Critical patent/JPWO2020246584A1/ja
Application granted granted Critical
Publication of JP7602457B2 publication Critical patent/JP7602457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021524929A 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント Active JP7602457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019106444 2019-06-06
JP2019106444 2019-06-06
PCT/JP2020/022293 WO2020246584A1 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント

Publications (2)

Publication Number Publication Date
JPWO2020246584A1 JPWO2020246584A1 (https=) 2020-12-10
JP7602457B2 true JP7602457B2 (ja) 2024-12-18

Family

ID=73652763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524929A Active JP7602457B2 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント

Country Status (8)

Country Link
US (1) US12016920B2 (https=)
EP (1) EP3981426A4 (https=)
JP (1) JP7602457B2 (https=)
KR (1) KR20220017919A (https=)
CN (1) CN113939313B (https=)
AU (1) AU2020288030A1 (https=)
TW (1) TW202112394A (https=)
WO (1) WO2020246584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157429A (ko) 2021-04-07 2023-11-16 덴카 주식회사 애주번트 활성 증강제 및 애주번트 조성물
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016515538A (ja) 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
ZA200707967B (en) 2005-04-08 2008-11-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
MX374090B (es) * 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2018013924A1 (en) * 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016515538A (ja) 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAE H.D.et al.，Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery，Mol.Pharmaceutics，2016年，Vol.13，pp.3196-3205
高山典子他，SPG-R8を用いたCpG-ODNの経鼻投与による粘膜免疫の賦活化，Drug Delivery System，2007年，Vol.22, No.3, ，p.395(2-P-65)

Also Published As

Publication number Publication date
TW202112394A (zh) 2021-04-01
WO2020246584A1 (ja) 2020-12-10
AU2020288030A1 (en) 2022-01-06
KR20220017919A (ko) 2022-02-14
EP3981426A1 (en) 2022-04-13
EP3981426A4 (en) 2023-06-07
CN113939313B (zh) 2024-11-01
JPWO2020246584A1 (https=) 2020-12-10
US12016920B2 (en) 2024-06-25
CN113939313A (zh) 2022-01-14
US20230330221A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
AU2007239354B2 (en) N protein fusion proteins of a virus in the Paramyxoviridae-protein of interest family
CN103446582A (zh) 包含诱导粘膜免疫的佐剂的新型疫苗
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
ES2924914T3 (es) Vacuna contra rinovirus humano
KR101751376B1 (ko) 점막 백신
WO2022229817A1 (en) Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US9198965B2 (en) Peptide adjuvant for influenza vaccination
US20190337989A1 (en) Immunity inducer
US20240207395A1 (en) Adjuvant activity enhancer and adjuvant composition
KR102523582B1 (ko) 바이러스 표면 엔지니어링 기반의 면역 증강된 바이러스 백신
JP2025528166A (ja) 狂犬病ｇタンパク質及びその使用
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
JP7651129B2 (ja) ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン
US20230373997A1 (en) Imdq-peg-chol adjuvant and uses thereof
WO2004066961A2 (en) Use of sendai virus as a human parainfluenza vaccine
JP2020050605A (ja) 粘膜アジュバント
KR20230057311A (ko) 바이러스 표면 엔지니어링 기반의 면역 증강된 바이러스 백신
WO2022210764A1 (ja) 経鼻投与インフルエンザワクチン
TW202500574A (zh) 冠狀病毒刺突醣蛋白受體結合域及其用途
CN117425667A (zh) 基于病毒表面工程的免疫增强的病毒疫苗
JP2023518427A (ja) ハプテン化コロナウイルススパイクタンパク質
HK1128077B (en) Intranasal influenza vaccine based on virosomes
JP2012219041A (ja) 経鼻投与用医薬組成物
HK1128077A1 (en) Intranasal influenza vaccine based on virosomes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241206

R150 Certificate of patent or registration of utility model

Ref document number: 7602457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150